Barry Clements

Barry Clements is a Clinical Associate Professor at the University of Western Australia (UWA) in the Paediatrics department within the UWA Medical School. His primary research focuses on cystic fibrosis, respiratory tract infections, and pediatric pulmonology. He has conducted multiple clinical trials evaluating novel therapies for cystic fibrosis and respiratory infections, including studies on azithromycin, ethanol aerosols, and nebulizer technologies.

His research interests include drug delivery systems, antimicrobial treatments, and clinical pharmacology in pediatric populations. Notable contributions include the COMBAT CF trial assessing azithromycin's impact on lung disease progression in infants and a 2024 phase I trial evaluating inhaled ethanol's safety and pharmacokinetics.

Dr. Clements has secured grants from Vertex Pharmaceuticals for cystic fibrosis drug efficacy studies and safety evaluations. He collaborates on projects addressing structural lung disease, viral load reduction in influenza models, and optimizing aerosol therapy for children with tracheostomies.

His work has been published in high-impact journals like The Lancet Respiratory Medicine and Journal of Cystic Fibrosis, with a focus on translating laboratory findings into clinical practice. He leads multiple active research projects investigating long-term safety and efficacy of cystic fibrosis therapies.